📥 FREE DOWNLOAD
For research professionals only — instant download, no payment required
What Is Ipamorelin? Complete Selective GHRP Research Peptide Guide for UK Laboratory Research
What is Ipamorelin? Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHRP) that acts as an agonist at the Growth Hormone Secretagogue Receptor 1a (GHSR-1a, also known as the ghrelin receptor). In the original rat and swine studies it released GH without raising ACTH or cortisol beyond the levels seen with GHRH, unlike GHRP-6 and GHRP-2 (Raun et al., 1998).
This selectivity of GH release, rather than exclusive receptor binding, is the property that distinguishes Ipamorelin from earlier GHRPs. Ipamorelin is often studied alongside CJC-1295 in combined GHRH and GHRP research designs.
Ipamorelin is supplied for in-vitro laboratory research only. It is not a licensed medicinal product under the UK Human Medicines Regulations 2012, and no dosing or administration guidelines are provided in this guide or in any Ascend Peptides UK documentation.
The compound is supplied to qualified research professionals (laboratories, academic institutions, research scientists) for in vitro cellular and endocrine pathway research applications. The published Janoshik certificate for Ipamorelin 10mg reports purity and measured content for one tested vial (the batch reference and results are listed on the CoA page); it does not separately report an LC-MS identity result, and no certificate is currently published for the 5mg format.
📥 FREE DOWNLOAD
For research professionals only — instant download, no payment required
What Is Ipamorelin at the Molecular Level?
Ipamorelin is a synthetic 5-amino acid peptide (a pentapeptide) with structurally distinctive non-natural amino acid substitutions, including Aib (2-aminoisobutyric acid) and D-2-naphthylalanine residues.
The compound is supplied to laboratories as a lyophilised (freeze-dried) white powder for reconstitution before in vitro research use. The molecular structure and key chemistry properties of Ipamorelin are documented below.
|
Molecular Property |
Value |
|---|---|
|
Compound name |
Ipamorelin (Selective GHRP, Growth Hormone Secretagogue) |
|
Peptide class |
Pentapeptide (5 amino acid sequence) |
|
Amino acid sequence |
Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
|
Key modifications |
2-aminoisobutyric acid (Aib) position 2, D-2-naphthylalanine position 3, C-terminal amide |
|
Molecular formula |
C38H49N9O5 |
|
Molecular weight |
≈ 711.85 Da |
|
Receptor target |
GHSR-1a (Growth Hormone Secretagogue Receptor 1a, the ghrelin receptor) |
|
Selectivity |
Selective GH release: no ACTH or cortisol rise beyond GHRH levels in rat and swine studies (Raun et al., 1998) |
|
Supplied format |
Lyophilised white powder for reconstitution |
|
Storage |
Being confirmed with the manufacturer |
Earlier-generation GHRPs such as GHRP-2 and GHRP-6 also act at GHSR-1a but, in the original comparative studies, raised ACTH and cortisol as well as GH.
Ipamorelin did not produce this ACTH and cortisol rise in those studies (Raun et al., 1998). This selectivity is what makes Ipamorelin analytically useful in research protocols where the experimental design requires isolating the GHSR-1a signalling pathway from cross-pathway effects.
LC-MS analysis can confirm molecular identity by matching the measured molecular weight against the theoretical value (≈ 711.85 Da). Current Ascend Janoshik certificates do not separately report an LC-MS result. The complete laboratory quality control workflow is documented on the how we test peptides page.
How Does Ipamorelin Work in Cellular Research Models?
Ipamorelin acts as an agonist at the Growth Hormone Secretagogue Receptor 1a (GHSR-1a), which is the receptor for the endogenous peptide ghrelin. The GHSR-1a is expressed on pituitary somatotrophs (the growth hormone-producing cells of the anterior pituitary) and in several other tissues, including the hypothalamus. Receptor activation by Ipamorelin binding triggers the downstream signalling cascade, which in pituitary somatotroph research models stimulates growth hormone release through a pathway mechanistically distinct from the GHRHR pathway activated by CJC-1295.
The GHSR-1a Signalling Cascade
The GHSR-1a is a G protein-coupled receptor (GPCR) of the rhodopsin-like family, coupled primarily to Gq/11 proteins. Receptor activation by Ipamorelin binding triggers the following cellular signalling cascade in research models:
-
Ipamorelin binds and activates the GHSR-1a.
-
Receptor activation couples to Gq/11 protein and activates phospholipase C (PLC).
-
PLC hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG).
-
IP3 triggers intracellular calcium release from the endoplasmic reticulum.
-
In pituitary somatotroph research models, the rise in intracellular calcium is associated with growth hormone release.
Selectivity Profile: What Ipamorelin Does NOT Do
The defining research property of Ipamorelin is its selectivity. Earlier-generation GHRPs such as GHRP-6 and GHRP-2 also raised ACTH and cortisol in the original comparative studies; ipamorelin released GH with similar potency without that ACTH and cortisol rise (Raun et al., 1998). This makes Ipamorelin useful when an experimental design needs GH-axis activity with less adrenal-axis interference. It is often studied alongside CJC-1295 in combined GHRH and GHRP research designs. For the complete mechanism-level comparison between GHRH analogues and GHRPs, see GHRH vs GHRP: Mechanism Comparison.
Ipamorelin and CJC-1295: Combined GHRH and GHRP Research Designs
CJC-1295 and Ipamorelin are frequently paired in combined GH-axis research designs. The rationale for the combination is that the two compounds act at different receptors. CJC-1295 acts at the Growth Hormone Releasing Hormone Receptor (GHRHR) through the Gs-cAMP-PKA pathway.
Ipamorelin acts at the GHSR-1a through the Gq-PLC-IP3-calcium pathway. The two receptors are expressed on the same pituitary somatotroph cells but signal through completely different second messenger cascades. Combined GHRH and GHRP stimulation produced a synergistic (greater than additive) GH response in a published study using an earlier GHRP, which the authors interpreted as the two peptides acting through independent mechanisms (Bowers et al., 1990).
Why Receptor Differences Matter for Study Design
In a multi-compound design, compounds acting at different receptors can be varied separately, although their effects may still interact downstream. If two compounds in a research protocol both activate the same receptor or the same downstream signalling cascade, the experimental design cannot separate which compound contributes which effect.
The CJC-1295 plus Ipamorelin combination involves distinct signalling components at each step: different receptors (GHRHR vs GHSR-1a), different G proteins (Gs vs Gq/11), different second messengers (cAMP vs IP3-calcium). Because both pathways converge on GH release from the same somatotroph cells, their effects are not fully separable in a combined design, so single-compound control arms are needed.
|
Pathway Component |
CJC-1295 |
Ipamorelin |
|---|---|---|
|
Target receptor |
GHRH Receptor (GHRHR) |
GHSR-1a (ghrelin receptor) |
|
G protein |
Gs |
Gq/11 |
|
Effector enzyme |
Adenylyl cyclase |
Phospholipase C |
|
Second messenger |
cAMP |
IP3 + DAG |
|
Downstream kinase |
Protein kinase A (PKA) |
Intracellular Ca2+ release |
For UK research programmes running the CJC-1295 plus Ipamorelin combined protocol, the Somatic Axis Complex bundle from Ascend Peptides UK pairs both compounds at the reduced single bundle price of £50. Both compounds are sourced from a single supplier; this does not establish that the vials share a verified manufacturing lot.
Ipamorelin Research Applications in UK Laboratory Research
UK laboratory researchers working with Ipamorelin typically apply the compound across four research application areas. The application chosen depends on the specific experimental focus of the research programme.
Application 1: Selective GHSR-1a Receptor Pharmacology Research
Ipamorelin is used in GHSR-1a pharmacology research in pituitary cell models. Its selective GH-releasing profile (no ACTH or cortisol rise beyond GHRH levels in the original rat and swine studies) makes it analytically useful when the experimental design requires isolating GHSR-1a signalling from other receptor pathways.
Documented in-vitro research applications include receptor binding affinity studies, downstream signalling cascade research (Gq-PLC-IP3-calcium), and structure-activity relationship research within the GHRP compound family.
Application 2: Combined CJC-1295 plus Ipamorelin Multi Compound Research
A common Ipamorelin research design combines it with CJC-1295, activating the GHRH receptor and GHSR-1a together. Combined GHRH and GHRP stimulation has been reported to produce a synergistic GH response (Bowers et al., 1990). This combination is the reason Ipamorelin appears alongside CJC-1295 in the Ascend Peptides UK bundle range.
Application 3: Three-Compound GH Axis Research with IGF-1 LR3
For research programmes covering the complete GH axis from upstream growth hormone secretion through downstream IGF receptor signalling, Ipamorelin appears in three compound research protocols alongside CJC-1295 and IGF-1 LR3 (Insulin-like Growth Factor 1, Long R3 variant).
The three compound design covers upstream GHRHR activation (CJC-1295), parallel GHSR-1a activation (Ipamorelin), and downstream IGF-1 receptor signalling (IGF-1 LR3). The Anabolic Signal Complex bundle pairs all three compounds at £90 for combined GH axis research programmes.
Application 4: Selective GHRP Comparator Research
Within the broader GHRP research compound family, Ipamorelin can serve as a comparator against earlier-generation GHRPs such as GHRP-6 and GHRP-2, which in the original comparative studies also raised ACTH and cortisol (Raun et al., 1998).
Before Ordering Ipamorelin: Free Research Buyer Starter Pack
The Research Buyer Starter Pack is a free downloadable guide for UK research buyers evaluating peptide suppliers. It converts the documentation framework into a practical buyer checklist covering exactly what to verify before ordering Ipamorelin or any other research peptide. Run any supplier against the checklist, including Ascend Peptides UK, to confirm the documentation standard before purchase.
📥 FREE DOWNLOAD
Research Buyer Starter Pack
A practical guide for UK research buyers. What to check before ordering a metabolic research peptide. What documentation to request from any supplier? What storage and dispatch standards to expect.
Inside the checklist:
Inside the pack:
✓ What “research-use only” means under UK regulation
✓ How to evaluate a UK research peptide supplier — 9-point checklist
✓ What documentation to request before purchase (CoA, HPLC, LC-MS)
✓ What storage and reconstitution standards to verify
✓ Pre-order buyer checklist — 16 items to confirm
✓ How to spot a low-quality metabolic peptide supplier — 7 warning signs
For research professionals only — instant download, no payment required
Ipamorelin Compared to Other Growth Hormone Research Compounds
The Ascend Peptides UK catalogue stocks five research compounds in the GH axis category, each acting on a different intervention point in the hypothalamic-pituitary-IGF axis. The defining variable across the five compounds is the receptor target. Ipamorelin acts at GHSR-1a (the ghrelin receptor). The three GHRH analogues (Sermorelin, CJC-1295, and Tesamorelin) all act at GHRHR. IGF-1 LR3 acts at the IGF-1 receptor downstream of growth hormone. See the GH axis research peptides category hub for the complete category framework.
|
Compound |
Compound Class |
Receptor Target |
Primary Research Application |
|---|---|---|---|
|
Ipamorelin |
Selective GHRP (pentapeptide) |
GHSR-1a (ghrelin receptor) |
Selective GHSR-1a pharmacology, GHRP family comparator |
|
Sermorelin |
Native GHRH analogue (29 AA) |
GHRHR |
Pulsatile GH release pharmacokinetic studies |
|
CJC-1295 |
Modified GHRH analogue (29 AA) |
GHRHR |
GHRHR pharmacology, often paired with Ipamorelin |
|
Tesamorelin |
Full-length GHRH analogue (44 AA) |
GHRHR |
Full-length GHRH analogue comparison research |
|
IGF-1 LR3 |
IGF-1 variant (downstream) |
IGF-1 receptor |
Downstream IGF signalling research |
Ipamorelin UK Supplier Standards: What to Verify Before Purchase
Ipamorelin contains non-natural amino acid substitutions that are technically demanding to synthesise correctly, which makes identity documentation relevant. Four documentation standards distinguish a verified UK supplier of Ipamorelin from an unverified one. The complete framework is set out on the batch verification page.
|
Documentation Standard |
Industry Norm |
Ascend Peptides UK |
|---|---|---|
|
HPLC purity verification |
Self-reported by the supplier |
Independent HPLC by Janoshik for a tested 10mg sample; results on the CoA page |
|
LC-MS molecular identity |
Often not performed |
Not separately reported on current Janoshik certificates |
|
Batch-specific Certificate of Analysis |
Generic or unavailable |
Certificate names the batch tested (10mg); none published yet for 5mg |
|
UK dispatch standards |
3 to 7 working days |
Same working-day UK dispatch on in-stock orders before 3pm (Mon–Fri) |
The published Janoshik certificate for Ipamorelin 10mg states measured content and purity for the batch tested. It does not separately report an LC-MS identity result, so it does not by itself confirm the non-natural Aib and D-naphthylalanine substitutions. The Janoshik Certificate of Analysis is publicly accessible from the CoA archive before the order is placed. For the complete research grade standards framework, see the research grade standards page.
Ipamorelin Storage Information
Lyophilised Ipamorelin is supplied in a sealed glass vial; storage conditions are being confirmed with the manufacturer.
Ascend Peptides UK does not publish reconstitution, solvent or in-use instructions; these are decisions for your own validated laboratory protocol. General background is in the peptide storage guide.
What Ascend Currently Publishes About Ipamorelin Storage
-
Lyophilised Ipamorelin: storage conditions are being confirmed with the manufacturer.
-
Solvent choice: a decision for your own validated laboratory protocol; Ascend does not specify one.
-
Prepared solutions: Ascend does not publish storage conditions for prepared solutions.
-
In-use period: not published by Ascend Peptides UK.
-
Published literature notes that repeated freeze-thaw cycles can promote peptide aggregation.
Ipamorelin in Combined Research Bundles
Ipamorelin appears in four Ascend Peptides UK research bundles, each designed for a specific multi-compound research protocol. Bundles supply the compounds from a single supplier at a reduced unit cost.
|
Bundle |
Compounds Included |
Price |
Research Application |
|---|---|---|---|
|
Somatic Axis Complex |
CJC-1295 (Without DAC) 10mg + Ipamorelin 10mg |
£50 |
Combined GHRH + GHRP research design |
|
Anabolic Signal Complex |
IGF-1 LR3 1mg + CJC-1295 (Without DAC) 10mg + Ipamorelin 10mg |
£90 |
Three-compound GH axis + downstream IGF research |
|
Metabolic Pathway Complex |
AOD-9604 5mg + CJC-1295 (Without DAC) 10mg + Ipamorelin 10mg |
£85 |
GH axis + lipolytic metabolic combined research |
|
Full Stack |
BPC-157 10mg + TB-500 10mg + CJC-1295 (Without DAC) 10mg + Ipamorelin 10mg |
£100 |
Four-compound multi-pathway research design |
The Somatic Axis Complex pairs Ipamorelin with CJC-1295 for combined GHRH and GHRP research designs. The Anabolic Signal Complex adds IGF-1 LR3 for research programmes covering the downstream IGF pathway.
The Metabolic Pathway Complex pairs Ipamorelin and CJC-1295 with AOD-9604 for combined GH axis and metabolic pathway research. The Full Stack bundle covers Ipamorelin and CJC-1295 alongside the recovery research compounds BPC-157 and TB-500 for comprehensive four-compound multi-pathway research designs.
Why UK Researchers Source Ipamorelin from Ascend Peptides UK
- Independent HPLC purity analysis by Janoshik for a tested Ipamorelin 10mg sample (results on the CoA page).
- LC-MS identity data is not separately reported on current Janoshik certificates.
- Publicly verifiable Certificate of Analysis naming the batch tested.
- Same working-day UK dispatch on in-stock orders before 3pm (Mon–Fri) via Royal Mail Tracked 24.
- FREE 10ml bacteriostatic water on orders of £75 or more.
- Bundle options available: Somatic Axis Complex (£50), Anabolic Signal Complex (£90), Metabolic Pathway Complex (£85), Full Stack (£100).
- Complete GH axis research peptide range (CJC-1295, Sermorelin, Tesamorelin, IGF-1 LR3 and Ipamorelin) stocked together from a single supplier.
What Is Ipamorelin? Frequently Asked Questions
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (5 amino acid sequence) growth hormone secretagogue (GHRP) that acts as an agonist at the Growth Hormone Secretagogue Receptor 1a (GHSR-1a, the ghrelin receptor). The amino acid sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2 with non-natural substitutions at positions 2 and 3. The molecular formula is C38H49N9O5, and the molecular weight is approximately 711.85 Da.
What makes Ipamorelin a “selective” GHRP?
In the original rat and swine studies, earlier GHRPs such as GHRP-6 and GHRP-2 raised ACTH and cortisol as well as GH. Ipamorelin released GH with similar potency without raising ACTH or cortisol beyond the levels seen with GHRH, and did not affect FSH, LH, prolactin or TSH in those studies (Raun et al., 1998). “Selective” here refers to GH release relative to other pituitary hormones, not to exclusive receptor binding.
How does Ipamorelin differ from CJC-1295?
Ipamorelin and CJC-1295 act on completely different receptors through different second messenger cascades. CJC-1295 is a GHRH analogue acting at the GHRH Receptor (GHRHR) through the Gs-cAMP-PKA pathway. Ipamorelin is a GHRP acting at GHSR-1a (the ghrelin receptor) through the Gq-PLC-IP3-calcium pathway. Because the two compounds act at different receptors, they are often paired in combined research designs.
Why are CJC-1295 and Ipamorelin combined in research protocols?
The two compounds act at different receptors (GHRHR vs GHSR-1a), with different G proteins (Gs vs Gq/11) and second messengers (cAMP vs IP3-calcium). Combined GHRH and GHRP stimulation has been reported to produce a synergistic GH response (Bowers et al., 1990). The Somatic Axis Complex bundle from Ascend Peptides UK pairs both compounds at £50.
Is Ipamorelin the same as ghrelin?
No. Ipamorelin and ghrelin both bind the same receptor (GHSR-1a) but are structurally different compounds. Ghrelin is a 28-amino acid native peptide hormone with a specific octanoyl modification at serine 3. Ipamorelin is a synthetic 5-amino acid pentapeptide described in the original research as a selective GH secretagogue. Both are research compounds in the GHRP / ghrelin receptor research category.
What is the WADA status of Ipamorelin?
Ipamorelin is listed on the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is prohibited at all times for athletes subject to WADA jurisdiction. Ipamorelin supplied by Ascend Peptides UK is for in-vitro laboratory research only and is not represented as a substance for use by athletes or in any human or veterinary application.
What is the MHRA status of Ipamorelin in the UK?
Ipamorelin is not licensed as a medicinal product under the UK Human Medicines Regulations 2012. It is supplied strictly for in vitro laboratory research. The Medicines and Healthcare products Regulatory Agency (MHRA) is the relevant medicines regulator in the UK post Brexit (replacing the previous European Medicines Agency route).
How much does Ipamorelin cost from Ascend Peptides UK?
Ipamorelin is supplied at the individual product price from Ascend Peptides UK. Bundle options offer reduced unit pricing: the Somatic Axis Complex bundle (CJC-1295 + Ipamorelin) is £50, the Anabolic Signal Complex (adds IGF-1 LR3) is £90, and the Metabolic Pathway Complex (with AOD-9604) is £85. All orders of £75 or more qualify for a free 10ml bacteriostatic water.
Order Ipamorelin from Ascend Peptides UK: Same Working-Day Dispatch on In-Stock Orders
Browse the Ipamorelin product page for published Certificate of Analysis documentation and UK dispatch information. For combined GHRH and GHRP research designs, the Somatic Axis Complex bundle (CJC-1295 + Ipamorelin, £50) is available at a reduced bundle price. For the complete GH axis research category framework, see the GH axis research peptides UK page, or start with the main research peptides UK hub for the complete supplier model.
RESEARCH USE ONLY
All products supplied by Ascend Peptides UK are intended strictly for in-vitro laboratory research purposes only. Ipamorelin is not a licensed medicinal product under the UK Human Medicines Regulations 2012 and is not for human or veterinary use. No dosing or administration guidelines are provided. Products are supplied to qualified research professionals only.
📥 FREE DOWNLOAD
For research professionals only — instant download, no payment required